Phosphorus and calcium metabolism and the cardiovascular system in patients with early-stage chronic renal disease

  • Authors: Smirnov AV1, Volkov MM2, Dobronravov VA1, Rafrafi H3
  • Affiliations:
    1. Acad. I. P. Pavlov Saint Petersburg State Medical UniversityResearch Institute of Nephrology, Acad. I. P. Pavlov Saint Petersburg State Medical University
    2. Acad. I. P. Pavlov Saint Petersburg State Medical University
    3. Research Institute of Nephrology, Acad. I. P. Pavlov Saint Petersburg State Medical University
  • Issue: Vol 82, No 6 (2010)
  • Pages: 25-28
  • Section: Editorial
  • URL: https://ter-arkhiv.ru/0040-3660/article/view/30593
  • ID: 30593

Cite item

Full Text

Abstract

Aim. To define the impact of phosphorus and calcium metabolic disturbances in patients with early-stage chronic renal disease (CRD) on the cardiovascular system.
Subects and methods. The levels of phosphate (P), calcium, parathyroid hormone (PTH), 25(OH) vitamin D and 1,25(OH)2 vitamin D, serum lipidogram, carotid artery intima-media thickness (IMT), and X-ray degree of abdominal artery calcification (AAC) were determined and echocardiography, electrocardiography and blood pressure monitoring were made in 465 patients with Stages I-V CRD who did not receive renal replacement therapy (of them, 73.5% of the patients had early (I to III) stages).
Results. Blood 1,25(OH)2D was related inversely to left ventricular (LV) posterior wall thickness, blood pressure (BP), triglycerides, and the degree of AAC and correlated directly to the severity of LV diastolic dysfunction and inversely to IMT, the presence of coronary heart disease and heart failure (HF). ACC, LV hypertrophy, and arterial hypertension (AH) were more significant in patients with higher serum levels PTH and P.
Conclusion. In patients with early-stage CRD, phosphorus and calcium metabolic disturbances promote the development of AH, vascular and cardiac valvular calcification, myocardial hypertrophy, and HF.

About the authors

A V Smirnov

Acad. I. P. Pavlov Saint Petersburg State Medical UniversityResearch Institute of Nephrology, Acad. I. P. Pavlov Saint Petersburg State Medical University

Email: smirnov@nephrolog.ru
Кафедра пропедевтики внутренних болезнейд-р мед. наук, проф., зав., кафдир. НИИ нефрологии; СПбГМУ им. акад. И. П. ПавловаНаучно-исследовательский институт нефрологии Санкт-Петербургского государственного медицинского университета им. акад. И. П. Павлова; Acad. I. P. Pavlov Saint Petersburg State Medical UniversityResearch Institute of Nephrology, Acad. I. P. Pavlov Saint Petersburg State Medical University

M M Volkov

Acad. I. P. Pavlov Saint Petersburg State Medical University

Email: vmm58@mail.ru
Кафедра пропедевтики внутренних болезнейканд. мед. наук, ассистент; СПбГМУ им. акад. И. П. Павлова; Acad. I. P. Pavlov Saint Petersburg State Medical University

V A Dobronravov

Acad. I. P. Pavlov Saint Petersburg State Medical UniversityResearch Institute of Nephrology, Acad. I. P. Pavlov Saint Petersburg State Medical University

Email: dobronravov@nephrolog.ru
Кафедра пропедевтики внутренних болезнейд-р мед. наук, проф; СПбГМУ им. акад. И. П. ПавловаНаучно-исследовательский институт нефрологии Санкт-Петербургского государственного медицинского университета им. акад. И. П. Павлова; Acad. I. P. Pavlov Saint Petersburg State Medical UniversityResearch Institute of Nephrology, Acad. I. P. Pavlov Saint Petersburg State Medical University

H Rafrafi

Research Institute of Nephrology, Acad. I. P. Pavlov Saint Petersburg State Medical University

Кафедра пропедевтики внутренних болезнейаспирант; Научно-исследовательский институт нефрологии Санкт-Петербургского государственного медицинского университета им. акад. И. П. Павлова; Research Institute of Nephrology, Acad. I. P. Pavlov Saint Petersburg State Medical University

References

  1. Vanholder R., Massy Z., Argiles A. et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol. Dial. Transplant. 2005; 20 (6): 1048-1056.
  2. Levin A., Bakris G. L., Molitch M. et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007; 71: 31-38.
  3. Волков М. М. Биохимические показатели фосфорно-кальциевого обмена у пациентов с хронической болезнью почек I-V стадий. Нефрология 2009; 13 (3): 49-52.
  4. Voormolen N., Noordzij M., Grootendorst D. C. et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol. Dial. Transplant. 2007; 22 (10): 2909-2916.
  5. Kovesdy C. P., Ahmadadeh S., Anderson J. E., Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008; 73 (11): 1296-1302.
  6. Ravani P., Malberti F., Tripepi G. et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009; 75 (1): 88-95.
  7. Li Y. C., Kong J., Wei M. et al. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 2002; 110: 229-238.
  8. Mathieu C., Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol. Med. 2002; 8 (4): 174-179.
  9. Park C. W., Oh Y. S., Shin Y. S. et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am. J. Kidney Dis. 1999; 33 (1): 73-81.
  10. Zittermann A., Schleithoff S. S., Tenderich G. et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J. Am. Coll. Cardiol. 2003; 41 (1): 105- 112.
  11. Волков М. М., Дегтерева О. А., Шевякова Е. В. Факторы, связанные с кальцинацией клапанного аппарата сердца у пациентов на хроническом гемодиализе. Нефрология 2007; 11 (3): 57-63.
  12. Nasri H., Baradaran A. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis. J. Ayub. Med. Coll. Abbottabad. 2004; 16 (2): 3-8.
  13. Волков М. М., Смирнов А. В., Дегтерева О. А., Шевякова Е. В. Дисфункции миокарда, оцениваемые методом тканевой допплерографии и фосфорно-кальциевый баланс у пациентов на хроническом гемодиализе. Нефрология 2008; 12 (3): 18-23.
  14. El-Abbadi M. M., Pai A. S., Leaf E. M. et al. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int. 2009; (12): 1297-1307.
  15. Shioi A., Nishizawa Y. Roles of hyperphosphatemia in vascular calcification. Clin. Calcium. 2009; 19 (2): 180-185.
  16. Mathew S., Tustison K. S., Sugatani T. et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J. Am. Soc. Nephrol. 2008; 19 (6): 1092-1105.
  17. Hak A. E., Pols H. A. P., van Hemert A. M. et al. Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1926-1931.
  18. Zadshir A., Tareen N., Pan D. et al. The prevalence of hypovitaminosis D among US adults: data from the NHANES III. Ethn. Dis. 2005; 5 (4,suppl. 5): S97-S101.
  19. Wehmeier K. R., Mazza A., Hachem S. et al. Differential regulation of apolipoprotein A-I gene expression by vitamin D receptor modulators. Biochim. Biophys. Acta 2008; 1780 (2): 264-273.
  20. Linhartova K., Veselka J., Sterbakova G. et al. Parathyroid hormone and vitamin D levels are independently associated with calcific aortic stenosis. Circ. J. 2008; 72 (2): 245-250.
  21. Волков М. М., Дегтерева О. А., Смирнов А. В. и др. Атеросклероз как основной фактор кальциноза клапанного аппарата сердца в додиализном периоде хронической болезни почек. Нефрология 2007; 11 (4): 47-54.
  22. Joy M. S., Karagiannis P. C., Peyerl F. W. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J. Manag. Care Pharm. 2007; 13 (5): 397-411.
  23. Graciolli F. G., Neves K. R., dos Reis L. M. et al. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. Nephrol. Dial. Transplant. 2009; 24 (5): 1416-1421.
  24. Rashid G., Bernheim J., Green J., Benchetrit S. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am. J. Physiol. Renal. Physiol. 2007; 292 (4): 1215-1218.
  25. Bortotolotto L. A., Costa-Hong V., Jorgetti V. et al. Vascular changes in chronic renal disease patients with secondary hyperparathyroidism. J. Nephrol. 2007; 20 (1): 66-72.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies